Metronomic treatment significantly enhanced cytotoxicity in palbociclib-resistant ER-positive breast cancer cell lines

被引：0
|
作者：
Sherif, N. [1 ]
Ilari, A. [1 ]
Cordani, N. [1 ]
Grassilli, E. [1 ]
Cazzaniga, M. E. [1 ]
Lavitrano, M. [1 ]
Cerrito, M. G. [1 ]
机构：
[1] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 200卷
关键词：
D O I：
10.1016/j.ejca.2024.113825
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257 (PB-07
引用
收藏
页码：96 / 97
页数：2
相关论文
共 50 条
  • [41] PAK4 regulates sternness and progression in endocrine resistant ER-positive metastatic breast cancer
    Santiago-Gomez, Angelica
    Kedward, Thomas
    Simoes, Bruno M.
    Dragoni, Ilaria
    NicAmhlaoibh, Roisin
    Trivier, Elisabeth
    Sabin, Verity
    Gee, Julia M.
    Sims, Andrew H.
    Howell, Sacha J.
    Clarke, Robert B.
    CANCER LETTERS, 2019, 458 : 66 - 75
  • [42] Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
    Pandey, Kamal
    Katuwal, Nar Bahadur
    Park, Nahee
    Hur, Jin
    Cho, Young Bin
    Kim, Seung Ki
    Lee, Seung Ah
    Kim, Isaac
    Lee, Seung-Ryeol
    Moon, Yong Wha
    CANCERS, 2022, 14 (01)
  • [43] Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models (vol 9, 64, 2023)
    Hopcroft, Lorna
    Wigmore, Eleanor M.
    Williamson, Stuart C.
    Ros, Susana
    Eberlein, Cath
    Moss, Jennifer I.
    Urosevic, Jelena
    Carnevalli, Larissa S.
    Talbot, Sara
    Bradshaw, Lauren
    Blaker, Catherine
    Gunda, Sreeharsha
    Owenson, Venetia
    Hoffmann, Scott
    Sutton, Daniel
    Jones, Stewart
    Goodwin, Richard J. A.
    Willis, Brandon S.
    Rooney, Claire
    de Bruin, Elza C.
    Barry, Simon T.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [44] Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer
    Ditzel, Henrik J.
    Lyng, Maria B.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 376 - 377
  • [45] Metabolomic analysis as a tool to identify breast cancer (BC) cell lines resistant to palbociclib (PD)
    Bonechi, M.
    Guarducci, C.
    Meoni, G.
    Tenori, L.
    Biagioni, C.
    Schiff, R.
    Osborne, C. K.
    Luchinat, C.
    Malorni, L.
    Migliaccio, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
    D A Cameron
    D R Camidge
    J Oyee
    M Hirsch
    British Journal of Cancer, 2008, 99 : 1984 - 1990
  • [47] Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
    Cameron, D. A.
    Camidge, D. R.
    Oyee, J.
    Hirsch, M.
    BRITISH JOURNAL OF CANCER, 2008, 99 (12) : 1984 - 1990
  • [48] Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy
    Jeong, Hyehyun
    Kim, Sung-Bae
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [49] Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer
    Henrik J Ditzel
    Maria B Lyng
    Nature Clinical Practice Oncology, 2008, 5 : 376 - 377
  • [50] Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer
    Teruya, Natsuki
    Inoue, Hiroaki
    Horii, Rie
    Akiyama, Futoshi
    Ueno, Takayuki
    Ohno, Shinji
    Takahashi, Shunji
    CANCER MEDICINE, 2023, 12 (09): : 10526 - 10535
12345